USE OF NF-KB INHIBITION IN COMBINATION THERAPY FOR CANCER
First Claim
Patent Images
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor.
4 Assignments
0 Petitions
Accused Products
Abstract
The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
-
Citations
13 Claims
-
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (2, 3, 4, 5)
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
-
6. A method of enhancing chemotherapeutic cytotoxicity in a subject treated with an antineoplastic chemotherapeutic agent, comprising administering to the subject a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (7, 8)
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
-
9. A method of enhancing the cytotoxic effect of TNFα
- , comprising administering a therapeutically effective amount of NF-κ
B inhibitor in conjunction with the administration of TNFα
, whereby the cytotoxic effect of TNFα
is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (10)
- , comprising administering a therapeutically effective amount of NF-κ
-
11. A method of enhancing chemotherapeutic cytotoxicity in a subject treated with TNFα
- , comprising administering to the subject a therapeutically effective amount of NF-κ
B inhibitor in conjunction with the administration of TNFα
whereby the cytotoxic effect of TNFα
is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (12)
- , comprising administering to the subject a therapeutically effective amount of NF-κ
-
13. A method of screening a compound for the ability to reduce the antiapoptotic protective effects of an NF-κ
- B induced anti-apoptotic gene, comprising;
exposing a population of test cells to an anticancer treatment and a test compound;
determining cell viability after said exposure;
where reduced cell viability, compared to that which occurs in the absence of said test compound, indicates that said test compound reduces the anti-apoptotic effects of an NF-κ
B induced anti-apoptotic gene.
- B induced anti-apoptotic gene, comprising;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeUniversity of North Carolina At Chapel Hill (University of North Carolina System)
-
Original AssigneeUniversity of North Carolina At Chapel Hill (University of North Carolina System)
-
InventorsBALDWIN, ALBERT S., CUSACK, JAMES C., WANG, CUN-YU, MAYO, MARTY W.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/1
-
CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/4745 condensed with ring systems...A61K 31/70 Carbohydrates; Sugars; Deri...A61K 38/1709 from mammalsA61K 38/191 Tumor necrosis factors [TNF...
